Imagen de Portada

The NLRP3 inhibitor NT‐0796 enhances and sustains GLP‐1R agonist‐mediated weight loss in a murine diet‐induced obesity model

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Peter Thornton, Valérie Reader, Zsofia Digby, John Doedens, Nicola Lindsay, Nicholas Clarke, Alan P. Watt
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Low‐calorie diet‐induced weight loss is associated with altered brain connectivity and food desire in obesity
por: Hai Hoang, et al.
Publicado: (2024)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
por: Hans Johnson, et al.
Publicado: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
por: Zbigniew Siudak, et al.
Publicado: (2025)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
por: Tommaso Bucci, et al.
Publicado: (2025)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
por: W. Timothy Garvey, et al.
Publicado: (2024)

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
por: Jesse R. Richards, et al.
Publicado: (2024)

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
por: Calvin C. Wu, et al.
Publicado: (2025)

Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
por: Danna M. Breen, et al.
Publicado: (2025)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
por: Renata Spezani, et al.
Publicado: (2025)

Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
por: Megan O. Bensignor, et al.
Publicado: (2024)

Medical weight loss in older persons with obesity
por: Alessandro Gavras, et al.
Publicado: (2024)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
por: Huilin Tang, et al.
Publicado: (2025)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
por: Flora Lambert, et al.
Publicado: (2025)

Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
por: Ali Esparham, et al.
Publicado: (2024)

The effectiveness of multidisciplinary weight loss interventions is associated with initial cardiorespiratory fitness in adolescents with obesity
por: Brahim Allali, et al.
Publicado: (2024)

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
por: Franziska S. Ulrich, et al.
Publicado: (2026)

Alternate‐day fasting enhanced weight loss and metabolic benefits over pair‐fed calorie restriction in obese mice
por: Hadia Nawaz, et al.
Publicado: (2025)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice
por: Fen Long, et al.
Publicado: (2025)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
por: Teerapon Dhippayom, et al.
Publicado: (2025)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
por: Nicklas S. Klepser, et al.
Publicado: (2025)

Response to “Alternate‐day fasting enhanced weight loss and metabolic benefits over pair‐fed calorie restriction in obese mice”
por: Steven Swoap, et al.
Publicado: (2025)

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?
por: Michael Camilleri
Publicado: (2025)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
por: Lien‐Chung Wei, et al.
Publicado: (2025)

Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
por: Liang Zheng, et al.
Publicado: (2025)

SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis
por: Yu Bao, et al.
Publicado: (2024)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
por: Mario Luca Morieri, et al.
Publicado: (2026)

Lifestyle behavioral weight‐loss treatment for binge‐eating disorder in patients with obesity: where's the harm?
por: Sydney Yurkow, et al.
Publicado: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
por: Sama M. Abdel‐Rahman, et al.
Publicado: (2026)

Ethnic differences in weight loss during a clinical obesity management program
por: Jennifer Linchee Kuk, et al.
Publicado: (2025)

Features and behaviours for weight loss in the Chilean cohort with obesity from the ACTION study
por: Ada Cuevas, et al.
Publicado: (2024)

The role of incretin receptor agonists in the treatment of obesity
por: Thomas Forst, et al.
Publicado: (2024)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
por: Louise A. Donnelly, et al.
Publicado: (2025)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
por: João Sérgio Neves, et al.
Publicado: (2025)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
por: Christina Baechle, et al.
Publicado: (2024)

Risk related to gestational weight loss among individuals with obesity: a population‐based cohort study
por: Yanfang Guo, et al.
Publicado: (2024)

The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
por: Victoria Wen Wei Ng, et al.
Publicado: (2024)

Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
por: Yu Chang, et al.
Publicado: (2025)

Efficacy of GLP ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials
por: Armando Talavera, et al.
Publicado: (2025)

Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( SHR20004 ), a novel GLP ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
por: Yang Zou, et al.
Publicado: (2024)

Optimized RNA sequencing deconvolution illustrates the impact of obesity and weight loss on cell composition of human adipose tissue
por: Cheehoon Ahn, et al.
Publicado: (2025)